Tscan Therapeutics Share Price Today (NASDAQ: TCRX)

Name: Tscan Therapeutics Share Price (NASDAQ: TCRX) - Stock Quote, Live Chart
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Tscan Therapeutics share price is 1.25 & ₹107.06 as on 17 May 2025, 2.30 'hrs' IST

$1.25

▲

-0.06

(-4.96%)

Market is closed - opens 7 PM, 19 May 2025

View live Tscan Therapeutics share price in Dollar and Rupees. Guide to invest in Tscan Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Tscan Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Tscan Therapeutics share price movements

Today's Low: $1.24
Today's High: $1.30
$1.25
0.8%
Downside
Day's Volatility :4.62%
Upside
3.85%
52 Weeks Low: $1.02
52 Weeks High: $9.69
$1.25
18.4%
Downside
52 Weeks Volatility :89.47%
Upside
87.1%

Tscan Therapeutics (TCRX) Returns

Period	Tscan Therapeutics Inc	Index (Russel 2000)
3 Months	-38.06%	0.0%
6 Months	-70.36%	0.0%
1 Year	-86.45%	0.0%
3 Years	-59.18%	-0.3%

Tscan Therapeutics (TCRX) Key Statistics

in dollars & INR

Previous Close	$1.31
Open	$1.3
Today's High	$1.3
Today's Low	$1.24
Market Capitalization	$74.1M
Today's Volume	$311.3K
52 Week High	$9.69
52 Week Low	$1.02
Revenue TTM	$4.4M
EBITDA	$-136.2M
Earnings Per Share (EPS)	$-1.08
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-78.93%

How to invest in Tscan Therapeutics Stock (TCRX) from India?

It is very easy for Indian residents to invest directly in Tscan Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Tscan Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Tscan Therapeutics or TCRX on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Tscan Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Tscan Therapeutics shares which would translate to 0.685 fractional shares of Tscan Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India , including recognised companies like Tscan Therapeutics, in just a few clicks!

Returns in Tscan Therapeutics (TCRX) for Indian investors in Rupees

The Tscan Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Tscan Therapeutics investment value today

Current value as on today

₹16,333

Returns

₹83,667

(-83.67%)

Returns from Tscan Therapeutics Stock

₹86,398 (-86.4%)

Dollar Returns

₹2,731 (+2.73%)

Indian investors sentiment towards Tscan Therapeutics (TCRX)

-47%

Period: Apr 17, 2025 to May 17, 2025. Change in 30 Days versus previous period

Search interest for Tscan Therapeutics Stock from India on INDmoney has decreased by -47% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Tscan Therapeutics

EcoR1 Capital, LLC
8.84%
BlackRock Inc
8.77%
Adage Capital Partners Gp LLC
6.18%
Bvf Inc
5.28%
Baker Bros Advisors LP
4.92%
Vanguard Group Inc
4.21%

Analyst Recommendation on Tscan Therapeutics

Rating

Trend

Buy

91%Buy

8%Hold

0%Sell

Based on 12 Wall street analysts offering stock ratings for Tscan Therapeutics(by analysts ranked 0 to 5 stars)

Analyst Forecast on Tscan Therapeutics Stock (TCRX)

What analysts predicted

Upside of 620.0%

Target:

$9.00

Current:

$1.25

Insights on Tscan Therapeutics Stock (Ticker Symbol: TCRX)

Price Movement
In the last 1 month, TCRX stock has moved down by -13.5%
Increasing Revenue
Revenue is up for the last 2 quarters, 665.0K → 2.17M (in $), with an average increase of 69.4% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -35.80M → -34.12M (in $), with an average increase of 4.9% per quarter
TCRX vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 90.9% return, outperforming this stock by 177.0%
TCRX vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 122.2% return, outperforming this stock by 187.4%
Price to Sales
ForTCRX every $1 of sales, investors are willing to pay $16.0, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $15.6 for every $1 of sales.

Tscan Therapeutics Technicals Summary

Sell

Neutral

Buy

Tscan Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Tscan Therapeutics (TCRX) Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Tscan Therapeutics Inc	-18.63%	-70.36%	-86.45%	-59.18%	-88.14%
Regeneron Pharmaceuticals, Inc.	5.81%	-22.03%	-39.82%	-9.59%	6.55%
Vertex Pharmaceuticals Incorporated	-8.14%	-6.07%	-1.62%	71.71%	55.39%
Alnylam Pharmaceuticals, Inc.	22.5%	22.76%	89.78%	120.42%	100.22%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Tscan Therapeutics Inc	NA	NA	NA	-1.09	-0.79	-0.3	NA	3.71
Regeneron Pharmaceuticals, Inc.	14.86	14.86	1.26	35.5	0.16	0.07	0.01	277.5
Vertex Pharmaceuticals Incorporated	32.84	NA	2.59	18.0	-0.06	0.12	NA	64.2
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	1.06	-15.01	-0.02	NA	0.89

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Tscan Therapeutics Inc	Buy	$74.1M	-88.14%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$63.2B	6.55%	14.86	31.94%
Vertex Pharmaceuticals Incorporated	Buy	$111.5B	55.39%	32.84	-8.91%
Alnylam Pharmaceuticals, Inc.	Buy	$34.9B	100.22%	NA	-11.49%

About Tscan Therapeutics

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT) is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also advanced TS-102 into IND-enabling activities. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors. It has collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Organization	Tscan Therapeutics
Employees	200
CEO	Dr. Stephen J. Elledge Ph.D.
Industry	Miscellaneous

Management People of Tscan Therapeutics

Name	Title
Dr. Stephen J. Elledge Ph.D.	Co-Founder & Chairman of Scientific Advisory Board
Mr. Tomasz Kula Ph.D.	Co-Founder & Member of Advisory Board
Dr. Justin McCue Ph.D.	Chief Technology Officer
Ms. Ann Hargraves	Senior Vice President of Human Resources
Dr. Shrikanta Chattopadhyay M.D.	Senior VP & Head of Translational Medicine
Mr. Ray Lockard M.B.A.	Senior Vice President & Head of Quality
Mr. Jim Murray	Senior VP & Head of Development Operations
Mr. Cagan Gurer Ph.D.	Senior Vice President of Discovery
Mr. Stephen Camiolo	Senior Vice President of Market Access

Important FAQs about investing in TCRX Stock from India :

Can Indians buy Tscan Therapeutics shares?

Yes, Indians can invest in the Tscan Therapeutics (TCRX) from India.

With INDmoney, you can buy Tscan Therapeutics at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Tscan Therapeutics at zero transaction cost.

How can I buy Tscan Therapeutics shares from India?

It is very easy to buy Tscan Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Tscan Therapeutics (TCRX) be purchased?

Yes, you can buy fractional shares of Tscan Therapeutics with INDmoney app.

What are the documents required to start investing in Tscan Therapeutics stocks?

To start investing in Tscan Therapeutics, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What is Tscan Therapeutics share price today?

Tscan Therapeutics share price today stands at $1.25, Open: $1.30 ; Previous Close: $1.31 ; High: $1.30 ; Low: $1.24 ; 52 Week High: $9.69 ; 52 Week Low: $1.02.

The stock opens at $1.30, after a previous close of $1.31. The stock reached a daily high of $1.30 and a low of $1.24, with a 52-week high of $9.69 and a 52-week low of $1.02.